



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ro 25-6981 Maleate

Cat. No.:	HY-13993A
CAS No.:	1312991-76-6
Molecular Formula:	C ₂₆ H ₃₃ NO ₆
Molecular Weight:	455.54
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (219.52 mM; Need ultrasonic)					
	H ₂ O : 8.33 mg/mL (18.29 mM; ultrasonic and warming and heat to 45°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.1952 mL	10.9760 mL	21.9520 mL
		5 mM		0.4390 mL	2.1952 mL	4.3904 mL
10 mM			0.2195 mL	1.0976 mL	2.1952 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline					
	Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)					
	Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 5 mg/mL (10.98 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleate shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) ^{[1][2][3]} .
IC ₅₀ & Target	NMDA Receptor
In Vivo	Ro 25-6981 Maleate (0.39-12.5 mg/kg; i.p.) induces contraversive rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats without stimulating locomotion in normal rats ^[1] .

?Ro 25-6981 Maleate (1,3 mg/kg; i.p.) exhibits age- and activation-dependent anticonvulsant action at early postnatal development in rats^[2].

?Ro 25-6981 Maleate (800 µg; intrathecal injection) shows significant analgesic effects on incision pain in rats and effectively attenuated postoperative hyperalgesia induced by remifentanyl^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-OHDA-lesioned rats ^[1]
Dosage:	0.39-12.5 mg/kg
Administration:	i.p.
Result:	Dose-dependently induced contraversive tight nose-to-tail rotations, and induced a weak ipsiversive circling response indicating a mild unspecific stimulatory action of the compound.
Animal Model:	Male albino rats of Wistar strain ^[2]
Dosage:	1, 3 mg/kg
Administration:	i.p.
Result:	Caused a significant decrease of N1-P2 amplitude at higher stimulation intensities AT 3 mg/kg, and exhibited age- and activation-dependent anticonvulsant action at early postnatal development.

CUSTOMER VALIDATION

- Cell Death Differ. 2023 May 4.
- CNS Neurosci Ther. 2023 Jan 24.
- Neuropharmacology. 2022 Jan 10;108947.
- Sci Rep. 2022 Oct 12;12(1):17114.
- Neurochem Int. 2020 Dec 16;104942.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Löschmann PA, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004 May;187(1):86-93.

[2]. Szczurowska E, et al. Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats. Brain Res Bull. 2015 Feb;111:1-8.

[3]. Jiang M, et al. Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor. Pharmacol Biochem Behav. 2013 Nov;112:56-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA